Wednesday 28 February 2024
Salisbury Foundation Trust


Internal Reference Number: FOI_6635

Date Request Received: 15/06/2022 00:00:00

Date Request Replied To: 22/06/2022 00:00:00

This response was sent via: By Email

Request Summary: Dermatology medication

Request Category: Companies

Question Number 1:
How many patients were treated in May 2022 (or latest available month) by the dermatology department with the following drugs:

• Abrocitinib (Cibinqo)
• Baricitinib (Olumiant)
• Bimekizumab (Bimzelx)
• Brodalumab (Kyntheum)
• Dupilumab (Dupixent)
• Ixekizumab (Taltz)
• Risankizumab (Skyrizi)
• Guselkumab (Tremfya)
• Secukinumab (Cosentyx)
• Tildrakizumab (Ilumetri)
• Tralokinumab (Adtralza)
• Upadacitinib (Rinvoq)
• Ustekinumab (Stelara)
Answer To Question 1:
Abrocitinib 0
Baricitinib 0
Bimekizumab 0
Brodalumab 8
Dupilumab 13
Ixekizumab <5
Risankizumab 0
Guselkumab 11
Secukinumab 5
Tildrakizumab <5
Tralokinumab 0
Upadacitinib 0
Ustekinumab 16
To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.

Person Centred & Safe





Salisbury NHS Foundation Trust, Salisbury District Hospital, Odstock Road, Salisbury, Wiltshire, SP2 8BJ
T: 01722 336262 E:
© 2024 Salisbury NHS Foundation Trust
Trust Values